Surrozen, Inc. (SRZN) Earnings
Surrozen, Inc. is expected to report next earnings on August 14, 2026 (in NaN days), with a consensus EPS estimate of $-1.29. SRZN has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -218.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $-1.39 | $-4.63 | -233.1% | $5M | +25.0% |
| Mar 23, 2026 | $-1.41 | $-7.59 | -438.3% | $528000 | -20.1% |
| Nov 7, 2025 | $-1.17 | $-3.61 | -208.5% | $983000 | — |
| Aug 8, 2025 | $-1.23 | $-1.14 | +7.3% | $983000 | — |
| May 9, 2025 | $-1.09 | $-3.13 | -187.2% | $983000 | — |
| Mar 31, 2025 | $-2.54 | $-9.10 | -258.3% | $655000 | — |
| May 8, 2024 | $-4.25 | $-4.24 | +0.2% | — | — |
| May 10, 2023 | $-5.10 | $-7.20 | -41.2% | — | — |
| Mar 22, 2023 | $-6.75 | $-0.45 | +93.3% | $13M | — |
| Nov 14, 2022 | $-6.45 | $-5.70 | +11.6% | — | — |
| Aug 11, 2022 | $-6.90 | $-6.00 | +13.0% | — | — |
| Mar 24, 2022 | $-7.80 | $-5.25 | +32.7% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2022 · March 25, 2023
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Surrozen is an innovator in using the Wnt pathway for tissue regeneration with proprietary technologies. - Focused on 2 key clinical areas: SZN-043 for severe alcoholic hepatitis and SZN-1326 for inflammatory bowel disease. - Updates on clinical trials: SZN-043 has enrolled first patient in chronic liver disease study, SZN-1326 to progress with modified dosing strategy. - Partnership with Boehringer Ingelheim, with potential milestone by year-end 2023. - Research programs for cornea, lacrimal gland, and ophthalmologic indications like dry eye.
Guidance
- Cash runway into second half of 2024. - SZN-043 expected to have data from Phase I single ascending dose in chronic liver disease patients by year-end 2023, Phase Ib in 2024. - SZN-1326 expected to have data by year-end 2023, Phase Ib in 2024. - Boehringer Ingelheim partnership to nominate candidate by year-end 2023, triggering $10M milestone.
Segment performance
No specific product segment financial performance with revenue contribution % discussed in detail
Risks & headwinds
- Transaminase elevations observed in clinical trials, not fully understood mechanistically. - Uncertainties in translating preclinical data to human responses, especially in hepatically-impaired patients. - Potential challenges in mitigating liver-related adverse events in more hepatically-impaired patients.
Analyst Q&A
Q: Clarification on SZN-043 study plans, change in target population from early cirrhotic to chronic liver disease, and strategy to mitigate transaminase observations in hepatically-impaired patients.
A: SZN-043 target population includes chronic liver disease patients with fibrosis, not necessarily frank cirrhosis. No specific mechanistic strategy to mitigate yet, but damaged tissue may be more sensitive.
Q: Half-life of SZN-1326 and expected dosing regimens for multiple ascending dose study.
A: Half-life of SZN-1326 is about 5 days. Dosing regimen not finalized, but could be every other week or less.
Q: Target engagement for SZN-043 and SZN-1326, dose response, and confidence in 0.5 dose for biological activity.
A: For SZN-043, target engagement confirmed via ALP elevation, 0.5 dose in range for potential therapeutic activity. For SZN-1326, target engagement to be confirmed by Axin2 assay in UC patient biopsies.